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Abstract Organ preservation with radiotherapy and con-
comitant chemotherapy has become an accepted treatment
modality in advanced head and neck cancer. Unfortunately,
organ preservation is not synonymous with function preser-
vation. The aim of this review was to systematically assess
the eVects of the disease and chemoradiotherapy (CRT) on
functions such as swallowing, mouth opening, nutrition,
pain and quality of life in patients with head and neck
cancer. Another aim was to search for (evidence-based)
techniques or strategies known to alleviate or rehabilitate
the loss of function(s) associated with CRT. Two databases
were searched (time period, January 1997 to August 2007)
for the terms head and neck cancer, chemotherapy or cis-
platin and radiotherapy, and the functional outcomes swal-
lowing, trismus, nutrition, pain and quality of life or a
variation of those words. In total, 15 relevant articles were
identiWed that met the inclusion criteria. The majority of the
studies that met the criteria focused on the outcomes swal-
lowing, quality of life, and nutrition. Two studies reported
on the outcome pain, but no paper reported on the outcome
trismus. Only two papers mentioned rehabilitation options,
but speciWc information was lacking. Further long-term
prospective research is essential, not only to determine the
function impairment caused by the tumor and CRT, but
also to assess the eVects of known and newly developed
rehabilitation measures. Therefore, in September 2006, the
Netherlands Cancer Institute started a randomised clinical
trial (RCT): Prevention of trismus, swallowing and speech
problems in patients treated with chemoradiotherapy for
advanced head and neck cancer. This systematic review
was carried out to collect the baseline information for the
future outcomes of this RCT.
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Introduction
Cancer is a major medical health problem worldwide with
annually more than 10 million new cases. For head and
neck, in 2002 there were 274,000 cases of oral cavity and
159,000 of laryngeal cancer [1] and these numbers are
steadily increasing [1]. With the advent of better surgical
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890 Eur Arch Otorhinolaryngol (2009) 266:889–900and reconstruction techniques and more eVective chemora-
diotherapy protocols, oncological outcomes have
improved, and thus increasing numbers of patients are con-
fronted with long-term negative side eVects of these indis-
pensable therapeutic interventions. Therefore, the
development and implementation of evidence-based strate-
gies for the prevention, treatment, and rehabilitation of
these side eVects are essential [2].
The major head and neck cancer sites are oral cavity,
oropharynx, larynx, hypopharynx, and nasopharynx [3].
Depending on the site and stage of the cancer, the treatment
may consist of surgery, radiotherapy, chemotherapy or a
combination with an increasingly important role for photo
dynamic therapy (PDT) [1, 4, 5]. For advanced cases, there
has been a shift from surgical treatment towards chemora-
diotherapy protocols (especially concomitant chemother-
apy and radiotherapy, CRT). These organ preservation
protocols, developed to maintain organ anatomy [6–12],
unfortunately do not necessarily preserve the organ’s func-
tion [5, 6, 10, 13, 14]. The toxicities of these combined
therapies are often severe and include xerostomia, pain,
mucositis, fatigue, as well as late eVects such as limited
mouth opening (trismus) [15, 16]. Fibrosis and muscle atro-
phy may also occur which can aVect swallowing as it
causes, for example, Wxation of the hyolaryngeal complex
and reduced glottic closure, potentially resulting in aspira-
tion [15, 17]. Rehabilitation that prevents and/or alleviates
the loss of function and increases the patients’ quality of
life therefore seems necessary. Several speciWc swallowing
exercises have the potential to improve prognosis for oral
intake (e.g., jaw exercises [18], swallowing exercises [19]
and maneuvres) [17, 20, 21]. It is, however, unknown
whether these standard exercises have a preventative eVect
in patients receiving CRT and whether the eVects, if any,
are maintained long-term.
The Wrst aim of this review was to examine the literature
to determine the eVect of the tumor and CRT on functions
such as swallowing, mouth opening, nutrition, as well as
quality of life and pain. A second aim was to search for
(evidence-based) therapy techniques and strategies that
may alleviate or even rehabilitate loss of function.
Methods
Electronic databases, Pubmed and Cochrane were searched
for the MeSH terms ‘chemotherapy or cisplatin and radio-
therapy’, ‘head and neck cancer’, ‘dysphagia or swallowing
disorders or swallowing dysfunction or deglutition’, ‘tris-
mus or limited mouth opening or mouth opening’, ‘quality
of life or QOL or questionnaire’, ‘oral intake or nutrition or
diet or weight changes or eating disability’ and ‘pain or
VAS scale’.
Inclusion criteria
Included in this review were clinical studies published from
1 January 1997 until 1 August 2007, written in Dutch, Ger-
man and English. Other limits were human and adults
(18 + years). Studies were included if they were research
based, published in a peer-reviewed journal, and reported
the use of concomitant chemoradiotherapy without any
other treatment modality for head and neck cancer.
Included studies had to report about functional problems or
rehabilitation options related to swallowing, trismus, qual-
ity of life, nutrition or pain. In addition, retrospective or
prospective studies that reported pre and postmeasurements
were also included.
Exclusion criteria
The following material was excluded: texts or practice
guidelines; studies that only reported outcomes related to
surgery, radiotherapy alone, radiotherapy followed by che-
motherapy or other kinds of drugs used during the treat-
ment; studies describing cancers other than primary cancer
in the oral cavity, nasopharynx, oropharynx, larynx or
hypopharynx; studies only reporting outcomes related to
survival, toxic eVects or general function (e.g. depression).
The intent of this review was to report on functional out-
comes and/or rehabilitation options after CRT, thus, details
related to surgical interventions, except the possible inXu-
ence of neck dissection, were not reviewed.
In total, 575 papers were identiWed in the databases. Of
these papers, 137 occurred more than once. The Wrst author
read the remaining 438 abstracts. Using the search strategy,
63 diVerent papers were initially identiWed as suitable
(Fig. 1) [9, 10, 13, 14, 22–80].
Two observers (LvdM and MR) assessed the selected
papers independently, according to speciWc criteria
designed for this study (Table 1): location of tumor, popu-
lation (i.e., N > 10), intervention, and outcome. Reference
lists from the selected review papers were analyzed for
other relevant citations [29, 75, 77]. These were then
obtained and subjected to the same process as the articles
retrieved from the database search. Of all references
searched manually, only one additional paper was selected
[81].
Finally, 15 papers answered all four speciWc criteria with
(yes) [13, 22, 23, 27, 34, 40, 42, 45, 51, 52, 59, 60, 65, 69,
81] (Fig. 1).1
1 A complete list of the papers retrieved from the databases is available
from the corresponding author. The Wfteen papers ‘surviving’ the pre-
deWned ‘quality’ criteria are listed in bold and the papers collected after
the reviewed period are listed bold and italic. 123
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The results of the selected Wfteen papers will be discussed
in the following order: general Wndings, relationships
between chemoradiotherapy (CRT) and swallowing, qual-
ity of life, trismus, nutrition, and pain. Since all these
papers discuss more than one of the issues listed here,
they will occur when relevant. An overview of these
papers and the aspects they have reported are presented in
Table 2.
General Wndings
Reported sites across all 15 articles included oral cavity
(10/15), nasopharynx (6/15), oropharynx (12/15), hypo-
pharynx (11/15) and larynx (13/15). Two studies also
included patients with unknown primaries [13, 52], one
also included paranasal sinuses [27], another included thy-
roid, paranasal sinus, and external ear cancer [81] and one
included a group with diverse disease sites (e.g., parotid,
ethmoid cavity, and unknown primary) [13, 27, 51, 52, 81].
Fig. 1 Search strategy
Table 1 Quality criteria
1.Were research question / objectives clearly stated    yes/no 
2.Were patient characteristics complete?       
Gender yes/no  Diagnosis yes/no  Site of lesion yes/no 
Age yes/no  T-stage yes/no  Treatment  yes/no 
         
3.Inclusion criteria: described explicity/ in detail      
  ylticilpmi debircsed        
4.Comparison & level of evidence (based on the Bandolier system, Moore et al, 1995 ):    
       4.none, retrospective only 2.prospective, ra    stnemtaert owt dezimodn
       3.prospective: pre and post treatment 2.prospective, randomized, two rehabilitation strategies 
       3.prospective: matched control group  1.systematic review, including RCTs 
5.Outcome:  i. evaluation tools standardised or validated;  yes/no 
 ;decnerefer ro         yes/no 
 srehcraeser eht yb detaerc ro        yes/no 
erusaem ekatni laro ,niap ,hceeps ,gniwollaws .ii   on/sey  ;yltcerid d
 ?eriannoitseuq LoQ a aiv ro         yes/no 
6.Were statistical analyses available?     yes/no 
7.Were results presented in clear tables and figures?    yes/no 
8.Drop-out and reporting of missing data:  were all     rof detnuocca stneitap 
 on/sey  ?)nevig tuo-pord rof snosaer(    
9. Replication potential?* yes/no 
10.Reliability checks reported:  (e.g. evaluation o   )ytilauq eciov evitpecrep ;gniwollaws f
 intra- or inter-judgment reliabilities of assessments given yes/no/n.a.** 
  
* treatment modalities described/ site of  
lesion in detail/ assessment replicable?   
** not applicable   123
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pre and posttreatment measurements varied per study. Fol-
low-up also varied, from immediately after treatment to
5 years posttreatment. Four articles also evaluated out-
comes during CRT [22, 27, 34, 51]. All articles reported on
treatment except two, that reported on swallowing rehabili-
tation [40, 64]. However, detailed information about the
type of rehabilitation was not reported. All the articles
stated clear research questions and/or objectives. Patient’s
characteristics were not available in three studies [27, 69,
81]. In one of these studies, the authors referred to a previ-
ous publication for those data [81] [82]. The T-stage was
reported in 8 of the 15 articles [13, 23, 27, 40, 42, 52, 59,
60, 69]. Several studies described only the overall stages
(III–IV). Exact sites of lesions were only reported in three
studies and included tonsil/lateral oropharynx, base of
tongue, Xoor of mouth, tongue, retromolar trigone/alveolar
process, transglottic or supraglottic larynx/vallecula, pha-
ryngeal wall, pyriform sinus/hypopharynx, glottic and buc-
cal mucosa tumors [23, 45, 59]. In most of the studies, the
inclusion criteria were described in detail.
The level of evidence of each study was graded using a
four-point-scale, based on the Bandolier system [83]. Only
two levels occurred, 3. prospective, pre and postmeasure-
ment and 2. prospective, randomized, two treatments. Sta-
tistical analyses and results were available and presented in
clear tables and Wgures in most articles. Three of the Wve
studies mentioned inter- and intra-observer reliability of
videoXuoroscopic modiWed barium swallow examination
(VMBS) [13, 40, 42, 52, 60]. For the other ten studies
(67%) this aspect was not applicable. Nine of 15 studies
(60%) reported reasons and extent of missing data, such as
patient drop out and death [4, 22, 23, 27, 34, 42, 45, 51, 60,
65]. Replication of two-thirds of these 15 studies would not
be possible as a result of missing information about
patients, and assessment methods.
Because of the main intent of this review, details related
to speech outcomes were not reviewed. Besides the out-
comes mentioned above, aspiration, swallowing therapy,
body weight, and tube feeding were assessed as well.
CRT and swallowing
Eight of the reviewed articles reported on swallowing func-
tion [13, 40, 42, 45, 52, 60, 65, 81]. Two studies used a
patient self-report questionnaire or a standardized quality-
of-life questionnaire [40, 45]. Both the studies concluded
that the patients’ abnormal swallowing, although improved,
was still present after 18 and 24 months. Goguen et al. [40]
used also a videoXuoroscopy examination, but only exam-
ined patients who had increased or protracted dysphagia
after treatment.
Table 2 Overview across all 15 studies














Quality of life 8/15














4. None, retrospective only 0/15
3. Prospective: pre and postmeasurement 11/15
3. Prospective: matched control group 0/15
2. Prospective, randomised two treatments 4/15
2. Prospective, randomised, two rehabs 0/15
1. Systematic review, including RCTs 0/15
Evaluation tools standardized or validated 12
Referenced 1
Created 2
Swallowing, trismus, pain etc.
Measured directly 8
Or via QOL questionnaire 5
Statistical analyses available 13/15
Results presented in clear tables and Wgures 15/15




Reliability checks reported 3/15123
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60, 65, 81]. All six studies reported several swallowing
abnormalities before treatment. The majority of studies
found the same disorders after CRT (range of follow-up: 1–
12 months for all studies), but in higher frequencies and in
greater severity. Logemann et al. [52] reported details of
the frequencies that occurred. Fifty-three subjects contrib-
uted 351 ‘swallows’ to the analysis before CRT. Swallow
disorders of varying severity occurred in the following fre-
quencies (percent of swallows in decreasing order):
reduced tongue base retraction (50%), reduced tongue
strength (39%), slowed/delayed laryngeal vestibule closure
(19%), reduced tongue control/shaping (17%), delayed
pharyngeal swallow (up to 30-s delay; 15%), reduced laryn-
geal elevation (13%), reduced manipulation and propulsion
of the bolus (reduced AP tongue movement; 12%), reduced
lateral/anterior tongue stabilization (7%), bilateral pharyn-
geal weakness (5%), reduced vertical tongue movement
(5%), reduced cricopharyngeal opening (3%), visible crico-
pharyngeal bar (2%), and unilateral pharyngeal weakness
(2%). At 3 months posttreatment, 53 patients contributed
310 swallows to the analysis, and the most frequently
occurring disorders were reduced tongue base retraction
(89%), reduced tongue strength (51%), and slowed/delayed
laryngeal vestibule closure (31%). The following disorders
occurred in less than 5% of the swallows: reduced lateral/
anterior tongue stabilization (5%), incomplete laryngeal
vestibule closure (5%), reduced velopharyngeal closure
(4%), reduced vertical tongue movement (3%), and reduced
glottic closure (1%). The other Wve studies did not report
any additional swallowing abnormalities. One study found
no obvious swallowing diVerences between early and late
posttreatment (1–3 and 6–12 months after CRT) [81].
Overall, the swallowing problems after CRT were moderate
to very severe.
Two studies reported a relationship between swallowing
diYculties and tumor site [52, 81]. Logemann et al. [52]
found that tumors in the nasopharynx had the highest fre-
quency of reduced oral tongue control. Tumors of the oro-
pharynx exhibited a high frequency of reduced tongue base
retraction, and reduced tongue strength. Tumors of the lar-
ynx had the highest frequency of reduced tongue base
retraction, reduced anterior posterior tongue movement,
delayed pharyngeal swallow, reduced laryngeal elevation,
and reduced cricopharyngeal opening. Tumors of unknown
origin had a high frequency of reduced laryngeal elevation,
reduced cricopharyngeal opening, and visible cricopharyn-
geal bar in spite of the fact that those patients received the
lowest average radiotherapy dose. However, no explanation
was attempted for this somewhat unexpected Wnding. Eisb-
ruch et al. [81] noted that swallowing abnormalities were
related to the stage of the primary tumor and its location,
but the advanced stage of all tumors (stage III/IV) and the
predominance of oropharyngeal primary tumors (14 of the
26 patients) precluded an analysis of these factors in their
study.
Nguyen et al. [65] also examined the swallows using
VMBS, relying on the swallowing performance scale (SPS)
to evaluate the severity of the swallow abnormalities pre
and posttreatment [65, 84]. These authors found that 27
patients (43%) had severe swallowing problems (grades 3–
7) before treatment, and after treatment (range 1–
10 months) this number increased to 48 patients (84%).
Number of neck dissections was reported in two studies
[40, 42]. Graner et al. [42] reported that seven patients with
neck dissections had signiWcantly worse laryngeal elevation
compared to the four patients who did not undergo this sur-
gery.
Aspiration
Seven studies analyzed the aspiration rate [13, 22, 40, 42,
52, 60, 65, 81]. The aspiration rate increased over time in
all studies. Eisbruch et al. [81] found that 3 of the 22
patients (14%) aspirated pretreatment, whereas 17 of 25
(68%) demonstrated aspiration in at least one of the post-
treatment measurements. Kotz et al. [13] reported no aspi-
ration in 12 patients before treatment compared to the 4
patients (33%) after treatment. This diVerence was, how-
ever, not signiWcant. Graner et al. [42] noted aspiration in 3
of 11 patients (27%) before treatment. Two of these
patients did not exhibit a cough reXex in response to mate-
rial entering the airway. After CRT (on average, 19 weeks),
seven patients (64%) aspirated and six of them had no
cough reXex in response to material entering the airway. In
the study by Nguyen et al. [64] (N = 63), three patients pre-
sented trace aspiration and seven severe aspiration at diag-
nosis (17% in total). Following treatment, 31 patients
(49%) aspirated. The aspiration attributed to CRT was 21
of the 63 patients (33%), which is a signiWcant increase in
aspiration rate. Logemann et al. [52] also found an increase
in aspiration rate. Four patients (8%) aspirated before treat-
ment and 12 patients (23%) after 3 months. These authors
also found that patients with lesions in the hypopharynx or
larynx most frequently aspirated before treatment when
compared with the other sites of disease. None of the other
studies mentioned diVerences by site of disease.
In two studies, pretreatment examination is missing [40,
60]. Newman et al. [60] described the aspiration rate per
bolus type, 1 month after treatment. Goguen et al. [40] per-
formed MBS when the perceived swallowing diYculties
were beyond that expected after treatment and found that
18 of 23 patients (78%) aspirated. Silent aspiration was
seen in 8 (35%) of these 23 cases.
In three studies, aspiration pneumonia occurred [22, 65,
81]. Abdel-Wahab et al. [22] reported three cases (13%) of123
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ruch et al. [81] found that 5 of the 17 cases (29%) with aspi-
ration on MBS developed aspiration pneumonia and of these
5, 2 died from their pneumonia. Nguyen et al. [65] reported
six patients (10%) who died from aspiration pneumonia [one
before, three during, and two after CRT (1–10 months)].
They also concluded that aspiration remained a signiWcant
morbidity of CRT for head and neck cancer patients.
Swallowing therapy
Two studies started swallowing therapy after VMBS in
patients with an abnormal swallow [40, 65]. In the study by
Goguen et al. [40], swallow therapy was undertaken by all
patients who showed laryngeal penetration without aspira-
tion. Exact details about the therapy were unavailable. Ngu-
yen et al. [65] reported that patients with severe swallowing
problems underwent swallow therapy immediately follow-
ing VMBS, prior to treatment. The swallowing therapy was
individualized for each patient. The therapy consisted
mostly of maneuvres to improve the eYciency and/or air-
way protection during the swallow. Patients identiWed with
an anatomic abnormality during the VMBS also applied
range of motion exercises. Based on posttreatment VMBS,
these authors concluded that the swallowing therapy was
frequently eVective in stopping aspiration.
CRT and quality of life
Eight of the reviewed papers reported on quality of life
questionnaires. [22, 23, 27, 34, 40, 42, 51, 69], using at
least one of the following standardized quality-of-life ques-
tionnaires: the University of Washington Quality of life
questionnaire (UWQol) [85], the Functional Assessment of
Cancer Therapy-General (FACT-G) [86], the Functional
Assessment of Cancer Therapy- Head and Neck question-
naire (FACT-HN) [86, 87], the Quality of Life Question-
naire C-30 (QLQ-C30) [88–90], the Quality of Life
Questionnaire-Head and Neck 35 (QLQ-HN35) [30, 91,
92], the European Organisation for Research and Treatment
of Cancer (EORTC/RTOG) [85, 93, 94], and the Perfor-
mance Status Scale for Head and Neck Cancer Patients
(PSS-HN) [95, 96]. Most of the studies reported signiWcant
improvement for most questionnaire scales over time.
Cohen et al. [34] found adverse eVect symptoms (e.g.
dry mouth, pain, sticky saliva, hoarseness) during treatment
as well as a signiWcant decline on performance items (e.g.
normalcy of diet, eating in public), FACT physical, func-
tional, head and neck subscales, and overall FACT-General
global QOL. The majority of scores returned to baseline
levels by 12 months.
List et al. [51] and Abdel-Wahab et al. [22] also mea-
sured an improvement at 12 months posttreatment, but List
et al. [51] reported that symptoms such as dry mouth, tast-
ing diYculties and soft food diet still occurred at
12 months. Patients also showed persistent diYculties in
the ability to eat all solid foods. Abdel-Wahab et al. [22]
reported a signiWcant decrease in mean scores (FACT-G)
during and immediately after CRT followed by a signiWcant
increase 6 months postCRT. The Total FACT-HN scores
reXected a signiWcant decrease in QOL for the Wrst
3 months, but this gradually increased, even 1 year post-
CRT.
Arraras Urdaniz et al. [27] described signiWcant diVer-
ences between the Wrst day of treatment and 1 month after
completing the treatment using the QLQ-C30 and QLQ-
H&N35. DiVerences were found in, for example fatigue
(C30), and in, for example dry mouth, decreased mouth
opening, social eating, sticky saliva, swallowing diYcul-
ties, and dental problems (H&N35). Comparison between
the last part of treatment and one-month posttreatment
revealed signiWcant diVerences, amongst others, in pain,
swallowing diYculties, dry mouth, tube feeding and weight
loss.
In contrast to the other studies, Oates et al. [69] reported
poorer quality-of-life scores for global health during the
24 months of follow-up; patients had progressive problems
with teeth, trismus, xerostomia, swallowing and social eat-
ing. However, this study only included 14 patients with
nasopharyngeal cancer.
There were no diVerences mentioned with respect to sex,
age, tumor site, or stage in any of the other studies.
CRT and trismus
Table 2 shows that none of the studies mentioned anything
about the outcome trismus or limited mouth opening. Of
the 63 collected papers, only 1 evaluated the occurrence of
trismus [71]. However, this article had to be excluded from
the Wnal analysis because there were only seven patients
who received CRT, and the results of this group were not
assessed separately.
CRT and nutrition
Seven papers analyzed the eVect of CRT on nutrition [40,
42, 45, 51, 52, 59, 69], of which four used validated
questionnaire (QOQ-C30, FACT-H&N or PSS-HN) [40,
42, 51, 69].
List et al. [51] reported that 30 (51%) of the patients
were eating a normal, unrestricted diet pretreatment.
Twelve patients (20%) were eating soft foods only, six
(10%) were taking liquids only, and seven (12%) were lim-
ited to non-oral intake. During treatment, there was a
marked decrease in the Normalcy of Diet subscale of the
PSS-HN. Comparing pre and posttreatment soft food diet123
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post vs. 42% pretreatment).
Graner et al. [42] reported that 9 (82%) of the 11 patients
reported no restrictions. After treatment, all patients but one
(90%) described increased diet restrictions. Moreover,
seven (64%) were taking less than 50% of nutrition orally
and relied on tube feeding as the primary means of nutri-
tional intake. In addition, restrictions in eating in public and
in normalcy of diet increased signiWcantly.
Goguen et al. [40] also described a decrease of oral
intake at 3 months. Only ten patients (17%) took a soft or
regular diet. After 12 months, this number increased to 47
of all patients (80%).
Oates et al. [69] found that oral feeding during treatment
with chemotherapy was the major problem, because
patients experienced nausea associated with chemotherapy
and were often unable to meet their nutritional require-
ments.
The other two studies measured nutrition using a scale or
a limited number of questions [45, 59]. Newman et al. [59]
used a 4-point scale created by the authors to measure the
eating ability of the patients. These authors found that at the
start of treatment, 18 patients (38%) reported normal eating
and 4 (8%) required a feeding tube. Eighteen months after
treatment, 41 patients (87%) were eating normally, with 34
(72%) reporting normal swallowing and 6 (13%) still
required a feeding tube.
Hillman et al. [45] only measured diet textures as
reported by the patients. At randomisation, 27–30% of the
44 patients who received CRT reported modiWcations in
diet texture. At 24 months posttreatment, only 21 patients
(13%) reported modiWcations in diet texture.
Overall, most studies reported some pretreatment changes
in diet, a decrease in oral intake during treatment, and
improved oral intake after 12–18 months posttreatment.
Body weight
The three papers evaluating body weight reported weight
loss during and after treatment [40, 59, 69]. Newman et al.
[59] reported a signiWcant 10% weight loss of pretherapy
body weight during treatment and a subsequent gain in
mean weight after treatment. After 18 months, the mean
weight loss, however, was still 8%.
Oates et al. [69] also reported a weight loss with a
median of 8.2 kg (range 2.3–13.9 kg), representing a pro-
portional weight loss of 4–17% during treatment. Weight
loss occurred despite support with enteral tube feeding. The
median weight loss during the full 2 years was 7 kg (range
2.3–17.3 kg) or 7.9% (range 3–22%). Goguen et al. [40]
found a median weight loss of 9.6 kg (12.7%). Unfortu-
nately, no long-term results or statistical analyses were
available for this latter study.
Tube feeding
Seven papers reported on tube feeding [22, 23, 40, 42, 52,
59, 69]. In six studies, placement occurred prior or during
the Wrst week of treatment [22, 23, 42, 52, 59, 69]. Only
Goguen et al. [40] performed placement after induction
chemotherapy. The number of patients with feeding tubes
varied from study to study. In the study by Newman et al.
[59], 4 patients (9%) had a feeding tube at the start of the
CRT, compared to 12 patients (26%) at completion. Loge-
mann et al. [52] reported eight patients (15%) with a gas-
trostomy tube before treatment and three patients (6%)
taking 50% or less of their nutrition orally. In the study of
Oates et al. [69], 13 patients (93%) required a gastrostomy
tube for nutritional support during treatment. Graner et al.
[42] reported that all patients were taking oral nutrition
before treatment, but eight patients (73%) had feeding tubes
placed either before or during their treatments because of
increased dysphagia. Also AckerstaV et al. [23] reported
that many patients used tube feeding at some time during
and/or after their treatment, but gave no numbers. In the
study by Abdel-Wahab et al. [22] and Goguen et al. [40] all
patients had to accept gastrostomy placement prior to or
during the Wrst week of treatment.
All studies measured a decrease of gastrostomy tube
dependency posttreatment. AckerstaV et al. [23] reported
that most patients regained more or less normal oral feed-
ing, but Wve patients (19%) still needed tube feeding at 1-
year follow-up: three because they had mastication prob-
lems, although drinking liquids was still possible, and two
because they could hardly swallow. Goguen et al. [40]
described that only 2 (3%) of 59 patients still had their
tubes after 2 years, one patient because of palliative che-
motherapy and one patient because he preferred keeping
his gastrostomy tube. In the study by Abdel-Wahab et al.
[22], 17 of the 21 (81%) were able to swallow solids 1-
year posttreatment, and all patients were independent of
tube feeding at 48 months. Newman et al. [59] looked at 6,
12 and 18 months posttreatment, and they found that the
need for a gastrostomy tube dropped to 13% (6 patients).
These authors concluded that subjects, who still had a
feeding tube after 6 months, were also dependent on tube
feeding after 12 and 18 months. Graner et al. [42] found
that seven patients (64%) were relying on tube feeding for
more than 50% of their nutrition and hydration 5 months
after treatment, and Logemann et al. [52] reported that 21
patients (40%) used tube feeding and 12 patients (23%)
were taking 50% or less of their nutrition orally after
3 months. Finally, in the study by Oates et al. [69], all
feeding tubes except one (8%) were removed 6 months
after treatment.
Overall, just one study reported that all patients were no
longer dependent on tube feeding after 4 years [22]. The123
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dependency up to 18 months after treatment.
CRT and pain
Two studies mentioned outcome (pain) in relation to the
CRT [23, 34]. In both the studies, pain was measured using
a standardized quality-of-life questionnaire (UWQol and
FACT-G). AckerstaV et al. [23] reported that 3 months
posttreatment, 12 patients (46%) needed regular (non-nar-
cotic) medication, and 2 patients (8%) suVered from severe
pain that had to be controlled by narcotics. [23] After
12 months, only Wve patients (19%) still required regular
medication for the pain. Cohen et al. [34] also reported a
signiWcant improvement in pain, 12 months posttreatment
compared to pretreatment [34].
Discussion
General
This review covered two research questions: (1) what are
the negative side eVects of concomitant CRT on swallow-
ing, mouth opening, pain and quality of life before and after
treatment in head and neck cancer patients and (2) what are
the rehabilitation options to ameliorate these side eVects?
Fifteen papers were identiWed that could be assessed
according to a predeWned set of ‘quality’ criteria. The
majority of these articles focussed on the outcomes swal-
lowing, quality of life and nutrition, but also on trismus and
pain.
In most papers, swallowing was assessed by means of
videoXuoroscopy modiWed barium examination (VBMS).
The most common abnormalities at baseline included
reduced posterior motion of the base of tongue, delay in
the swallow reXex, decreased epiglottic movement,
decreased laryngeal elevation, and bolus residue in the
vallecula or posterior pharyngeal wall after the comple-
tion of the swallow. The same swallowing abnormalities
occurred after CRT, but in higher frequencies and in
greater severity. Even 1-year posttreatment, swallowing
abnormalities still existed. Tumors in the nasopharynx
were associated with trismus and reduced oral tongue
control. Oropharynx tumors exhibited a high frequency of
reduced tongue base retraction and reduced tongue
strength and patients with lesions in the larynx most fre-
quently exhibit reduced tongue base retraction, reduced
anterior posterior tongue movement, delayed pharyngeal
swallow, reduced laryngeal elevation, and reduced crico-
pharyngeal opening. In addition, CRT seems to increase
the aspiration rate, and neck dissections seem to worsen
laryngeal elevation.
Most of the reviewed studies were not designed to exam-
ine the eVects of swallowing therapy, and therefore did not
focus on rehabilitation options. Many tongue and swallow-
ing exercises, such as tongue function therapy and swallow-
ing maneuvres, are described in the literature [17, 21, 48,
97–102]. Furthermore, the eVectiveness of these swallow-
ing exercises has not yet been assessed systematically in the
CRT patient population.
After the designated period of this systematic search had
ended, several additional papers were published, three of
which (Carroll et al. [97], Logemann et al. [103] and Lan-
german et al. [104]) warrant a brief review. Carroll et al.
and Logemann et al. suggested that (early) rehabilitation
might be beneWcial. Unfortunately, only limited numbers of
patients were involved and neither of these two studies was
a randomized clinical trail. Langerman et al. [104] retro-
spectively reviewed the incidences of aspiration after CRT
in 130 patients, and concluded that aspiration rate increases
over time. They also found that the patients with cancer of
the larynx and hypopharynx were more likely to be frank
aspirators (more than 5% of the swallowed bolus was aspi-
rated).
Quality of life research in the 15 assessed papers was
generally well conducted, which is not surprising in view of
the many well-designed and validated questionnaires pres-
ently available. In general, all papers reported that the over-
all quality of life scores improved over time and returned to
baseline 1 year postCRT.
To evaluate nutritional support, all the reviewed papers
used questionnaires or a 4-point-scale. Some studies
reported a gradual improvement of oral intake over time
and the majority of patients had returned to baseline levels
by 12 months. One study reported what might be a good
predictor; if the swallow is normal at 6 months posttreat-
ment, it will also be normal at 12 and 18 months [59]. The
data also suggest that the act of eating and swallowing itself
may ‘rehabilitate’ the oropharyngeal musculature necessary
for swallowing. In other words, keeping the muscles active
will keep the muscles useful.
We conclude that this systematic search of the literature
provides an answer to the Wrst research question, but that
the second question remains unanswered.
Limitations of current studies
Missing information, e.g. about gender, site of lesion, and
assessment methods precludes replication in two-thirds of
the studies. There was also little uniformity in follow-up
times and evaluation tools. Because missing data (drop-
outs) could have biased the results, lack of this information
is considered a limitation. In addition, only three of the Wve
relevant papers reported intra- or interobserver reliability
checks of VMBS.123
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ing, and in view of the more pronounced side eVects of
CRT in comparison to RT alone, more reports were
expected.
Finally, papers on rehabilitation options and their eVects
are very sparse. Most studies focussed on the functional
outcomes after CRT, but not on possible rehabilitation
options. The tradition of evidence-based rehabilitation after
organ sacriWcing therapies, such as total laryngectomy, has
been well-established and the time has now come to invest
in evidence-based rehabilitation after CRT [105].
Future directions
It is clear from the present systematic review that head and
neck cancer patients suVer from substantial function losses
after CRT. This implies that not only the various functions
at stake pre and posttreatment should be measured multidi-
mensionally but also that centers should strive at perform-
ing these measures with the same standardized, validated
instruments. In addition, prevention and rehabilitation of
loss of function should be investigated on a much wider
scale. The guidelines of the Dutch Cooperative Group on
Head and Neck Cancer already recommended preventative
management of trismus and dysphagia [3]. Other authors
also emphasize the importance of rehabilitation [5, 13, 15,
40].
Besides the swallowing intervention, rehabilitation of
trismus should be given attention. Dijkstra et al. [18] docu-
mented that, the eVects of therapeutic interventions of tris-
mus are hardly investigated and evidence supporting
prevention and treatment programs is generally not pro-
vided. Nevertheless, one randomised trial in patients who
had undergone radiotherapy for cancer of the head and neck
showed that standard stretching exercises with or without
the use of tongue depressors, and exercises with the passive
jaw moving device TheraBite, did increase mouth opening
signiWcantly [106]. As far as we know, it has not been
established if either standard stretching exercises or passive
movement using the TheraBite can prevent trismus. Burk-
head developed an exercise regimen incorporating the
TheraBite device, and found an increased neuromuscular
activation of the swallowing muscles (EVect of tongue and
jaw position on suprahyoids during swallowing. Paper pre-
sented at the ASHA Convention, session 1377, November
2004).
It is, however, uncertain at present which rehabilitation
procedures have the best preventative and long-term eVect
in decreasing functional problems such as swallowing,
mouth opening, pain and quality of life in patients with
head and neck cancer receiving CRT. The Netherlands
Cancer Institute started a Randomised Clinical Trail (pre-
vention of trismus, swallowing and speech problems in
patients treated with chemoradiotherapy for advanced head
and neck cancer in September 2006). This study compares
exercising with or without a device, and investigates if
either approach has a preventative or and long-term eVect
(1-year postCRT) on jaw motion and swallowing function.
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